Using expression and genotype to predict drug response in yeast.
Authors | |
Keywords | |
Abstract | Personalized, or genomic, medicine entails tailoring pharmacological therapies according to individual genetic variation at genomic loci encoding proteins in drug-response pathways. It has been previously shown that steady-state mRNA expression can be used to predict the drug response (i.e., sensitivity or resistance) of non-genotyped mammalian cancer cell lines to chemotherapeutic agents. In a real-world setting, clinicians would have access to both steady-state expression levels of patient tissue(s) and a patient's genotypic profile, and yet the predictive power of transcripts versus markers is not well understood. We have previously shown that a collection of genotyped and expression-profiled yeast strains can provide a model for personalized medicine. Here we compare the predictive power of 6,229 steady-state mRNA transcript levels and 2,894 genotyped markers using a pattern recognition algorithm. We were able to predict with over 70% accuracy the drug sensitivity of 104 individual genotyped yeast strains derived from a cross between a laboratory strain and a wild isolate. We observe that, independently of drug mechanism of action, both transcripts and markers can accurately predict drug response. Marker-based prediction is usually more accurate than transcript-based prediction, likely reflecting the genetic determination of gene expression in this cross. |
Year of Publication | 2009
|
Journal | PLoS One
|
Volume | 4
|
Issue | 9
|
Pages | e6907
|
Date Published | 2009 Sep 04
|
ISSN | 1932-6203
|
DOI | 10.1371/journal.pone.0006907
|
PubMed ID | 19730698
|
PubMed Central ID | PMC2731853
|
Links | |
Grant list | P50 GM071508 / GM / NIGMS NIH HHS / United States
50GM071508 / GM / NIGMS NIH HHS / United States
Howard Hughes Medical Institute / United States
|